Data integrity is one of the primary ways sponsors evaluate the maturity of a CDMO. Regulators worldwide continue to emphasize transparent, truthful, secure, and complete data as the foundation of GMP operations, and recent guidance from the U.S. Food and Drug Administration reinforces the expectation that firms must generate records that are accurate, contemporaneous, and trustworthy in all phases of drug development1. These ten tips offer practical ways CDMOs can strengthen their data culture and avoid the observations most frequently seen in FDA 483s and warning letters.
1. Make ALCOA+ a daily behavior, not a training slide
ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available) should guide every record created in manufacturing, QC labs, and development groups. The FDA has reiterated these expectations across multiple guidance documents1.
2. Use controlled, bound logbooks and never informal scratch notes
Loose pages, sticky pads, temporary worksheets, and untracked notes are incompatible with GMP requirements. Data must be traceable back to a controlled source.
3. Document activities in real time rather than at the end of a shift
Delayed documentation remains a common inspection finding. Reconstructed entries often conflict with instrument data, electronic logs, or other time-stamped systems.
4. Record deviations immediately to preserve accuracy and investigative clarity
When events are written down hours later, details are often forgotten or unintentionally revised. Regulators compare timestamps across systems, so accuracy is critical.
5. Support procedural controls with technical controls
Audit trails, version control, electronic signatures, and role-based access prevent intentional or unintentional manipulation of data. Relying only on SOP instructions is insufficient for modern GMP expectations2.
6. Require unique logins for every analyst and operator
Shared credentials undermine traceability, compromise investigations, and are routinely cited by FDA inspectors. Access must always be attributable to a specific individual.
7. Implement backup and recovery testing instead of assuming backups work
True data security requires routine restoration drills to confirm that archived data can be recovered completely and accurately.
8. Synchronize server clocks and instrument clocks across all systems
Misaligned timestamps can invalidate an entire data set during deviation or OOS investigations. Time synchronization is a technical control that directly supports ALCOA+.
9. Validate spreadsheets and small-scale digital tools
Any electronic calculation—spreadsheets, dilution sheets, assay calculators, or QC trackers—must be validated under 21 CFR Part 11 expectations. Small tools can create large compliance gaps if unvalidated3.
10. Reinforce data integrity as a cultural expectation
Frequent refresher training, routine walkthroughs, and leadership messaging help operators internalize data integrity principles. Most failures come from habits, not malicious intent.
References
- U.S. Food and Drug Administration. Data Integrity and Compliance with CGMP Guidance for Industry. https://www.fda.gov/media/119267/download ↩ ↩2
- European Medicines Agency (EMA). Guidance on Good Manufacturing Practice and Data Integrity. ↩
- World Health Organization (WHO). Technical Report Series on Data Integrity in Pharmaceutical Manufacturing. ↩